Company profile
Amgen Inc.
NASDAQ: AMGN · Healthcare · Drug Manufacturers - General
#19 of 1,418 Healthcare companies by revenue55th-percentile growth
EA Score
87AFH 90DQ 90GM 68SS 98
v0.1 · 65/100 weight · provisional
↑ market scale, Piotroski F · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$37.2B
Rev growth YoY (TTM)
+9.1%
Net income (FY)
$7.7B
Employees
31,500
as of 2026-08-04
Market cap
$204.5B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$36.8B$36.8B2025
Net income$7.7B$7.7B2025
Operating income$9.1B$9.1B2025
Total assets$90.6B$90.6B2025
Equity$8.7B$8.7B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Other Products21%
Prolia12%
Repatha9%
Otezla6%
ENBREL6%
EVENITY6%
By geography
UNITED STATES72%
Non-US28%
The read
What is Amgen Inc.’s revenue?
Amgen Inc. booked $36.8B in FY2025 revenue, growing 10.0% year over year — about the middle of the pack among Healthcare companies we track, at a 21.0% net margin.
Peers · Healthcare
Molina Healthcare, Inc.83B+Thermo Fisher Scientific Inc.86AAbbott Laboratories87AMedtronic plc84B+Gilead Sciences, Inc.87AMedline Inc.62CNeighbors
Ventura →Key facts
CEORobert A. Bradway
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersThousand Oaks, CA
ExchangeNASDAQ: AMGN
Employees31,500
IPO date1983-06-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.